Vaccines absorbable by the transmucosal way

Details Vaccines absorbable by the transmucosal way Vaccines absorbable by the transmucosal way

2005-08-30

2005-08-30

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S193100, C424S197110, C424S234100

Reexamination Certificate

active

06936250

ABSTRACT:
The main object of the present invention is to provide polysaccharide-coated antigens derivatized with lectins for pharmaceutical use. In the vaccines, polysaccharides are preferably selected from the group consisting of chitosan, low-molecular-weight and high-deacetylation-degree chitosan, methyl glycol chitosan, alginic acid, polymannuronic acid and salts or derivatives thereof. In the vaccines of the invention, antigens are microorganisms, infectious agents or constituents thereof, hormones, enzymes, proenzymes, narcotics, bioactive peptides, metabolites, biological precursors, cell constituents, allergens, and the lectins are of vegetable origin.

REFERENCES:
patent: 4470967 (1984-09-01), Gough et al.
patent: 5900238 (1999-05-01), Gombotz et al.
patent: 6048536 (2000-04-01), Chatfield
patent: 2053829 (1992-04-01), None
patent: 0491125 (1992-06-01), None
patent: WO0050078 (2000-08-01), None
Sorensen et al (Acta Pathologica Microbiologica et Immunologica Scandinavica vol. 92, No. 6, pp. 351-356, 1984).
Plotkin et al (VACCINES, published by W.B. Saunders Company, Philadelphia, 1988, p. 571).
McNeela EA, et al., “A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM (197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery”,Vaccine,pp. 1188-1198 (2000).
Jabbal-Gill I., “Stimulation of mucosal and systemic antibody responses againstBordetella pertussisfilamentous haemagglutin and recombinant pertussis toxin after nasal administration with chitosan in mice”,Vaccine,pp. 2039-2046 (1998).
Illum, L., “Chitosan and its Use as a Pharmaceutical Excipient”,Pharm. Res.,pp. 1326-1331 (1998).
Bacon et al., “Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens”,Infect. Immun.,pp. 5764-5770 (2000).
Mi FL et al., “Porous chistosan microsphere for controlling the antigen release of Newcastle disease vaccine preparation of antigen-adsorbed microsphere and in vitro release”Biomaterials,pp. 1603-1612 (1999).
Seferian et al., “Immune stimulating activity of two new chitosan containing adjuvant formulations”,Vaccine,pp. 661-668 (2000).
Baldrick, “Pharmaceutical excipient development: The Need for Preclinical Guidance”,Regul. Toxicol. Pharmacol.pp. 210-218 (2000).
Calvo et al. “Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines”,Pharm. Res.pp. 1431-1436 (1997).
Anderson, “Adjuvants and immunostimulants for enhancing vaccine potency in fish”,Dev. Biol Stand,pp. 257-265 (1997).
Aizpurua et al., “Oral Vaccination . . . Indentification of Classes of Proteins that Provoke an Immune Response upon Oral Feeding”,Journal of Exp. Medicine,pp. 440-451 (1998).
Pusztai et al., “Plant (Food) Lectins As Signal Molecules: Effects on the Morphology and Bacterial Ecology of the Small Intestine”,Lectin Reviews,pp. 1-15 (1991).

Affiliated with

Also associated with

Rating

Vaccines absorbable by the transmucosal way does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccines absorbable by the transmucosal way, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines absorbable by the transmucosal way will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3462868